Cargando…
Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study
We evaluated the antibody responses in 259 potential convalescent plasma donors for Covid-19 patients. Different assays were used: a commercial ELISA detecting antibodies against the recombinant spike protein (S1); a multiplex assay detecting total and specific antibody isotypes against three SARS-C...
Autores principales: | Terpos, Evangelos, Politou, Marianna, Sergentanis, Theodoros N., Mentis, Andreas, Rosati, Margherita, Stellas, Dimitris, Bear, Jenifer, Hu, Xintao, Felber, Barbara K., Pappa, Vassiliki, Pagoni, Maria, Grouzi, Elisavet, Labropoulou, Stavroula, Charitaki, Ioanna, Ntanasis-Stathopoulos, Ioannis, Moschandreou, Dimitra, Bouhla, Anthi, Saridakis, Stylianos, Korompoki, Eleni, Giatra, Chara, Bagratuni, Tina, Pefanis, Angelos, Papageorgiou, Sotirios, Spyridonidis, Alexandros, Antoniadou, Anastasia, Kotanidou, Anastasia, Syrigos, Konstantinos, Stamoulis, Konstantinos, Panayiotakopoulos, George, Tsiodras, Sotirios, Alexopoulos, Leonidas, Dimopoulos, Meletios A., Pavlakis, George N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760522/ https://www.ncbi.nlm.nih.gov/pubmed/33260775 http://dx.doi.org/10.3390/microorganisms8121885 |
Ejemplares similares
-
Rapid Reduction of Anti-Sars-Cov-2 Antibodies in Convalescent Plasma Donors; Results of a Phase 2 Clinical Study
por: Terpos, Evangelos, et al.
Publicado: (2020) -
Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma
por: Thomopoulos, Thomas P., et al.
Publicado: (2021) -
A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis
por: Pappa, Vasiliki, et al.
Publicado: (2021) -
SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors
por: Terpos, Evangelos, et al.
Publicado: (2021) -
P1629: ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL
por: Thomopoulos, T., et al.
Publicado: (2022)